Third CECOG consensus on the systemic treatment of non-small-cell lung cancer

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1223-1229

  Brodowicz, T ^a,b   Ciuleanu, T ^c   Crawford, J ^d   Filipits, M ^a   Fischer, J R ^e   Georgoulias, V ^f   Gridelli, C ^g   Hirsch, F R ^h   Jassem, J ^b,i   Kosmidis, P ^j   Krzakowski, M ^b,k   Manegold, Ch ^l   Pujol, J L ^m   Stahel, R ⁿ   Thatcher, N ^o   Vansteenkiste, J ^p   Minichsdorfer, C ^a   Zochbauer Muller S ^a   Pirker, R ^a   Zielinski, C C ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Central European Cooperative Oncology Group   (Austria)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Klinik Lowenstein   (Germany)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^g SG Moscati Hospital   (Italy)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j HYGEIA HOSPITAL   (Greece)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m HÔPITAL ARNAUD DE VILLENEUVE   (France)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o CHRISTIE HOSPITAL   (United Kingdom)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

CECOG; Chemotherapy; NSCLC; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ACNE; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CONSENSUS DEVELOPMENT; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE QUALITY; HUMAN; INFUSION RELATED REACTION; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84860461190     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr381     Document Type: Article

References (55)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3): 581-592.
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123 (1 Suppl): 21S-49S.
3. Zielinski CC, Beinert T, Crawford J et al. Consensus on medical treatment of non-small-cell lung cancer-update 2004. Lung Cancer 2005; 50: 129-137.
4. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20(11): 1771-1785.
5. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355(9202): 479-485.
6. Nesbitt JC, Putnam JB Jr., Walsh GL et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995; 60(2): 466-472.
7. Rami-Porta R, Ball D, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2(7): 593-602.
8. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350(4): 351-360.
9. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7(9): 719-727.
10. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95(19): 1453-1461.
11. Strauss GM, Herndon JE 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26(31): 5043-5051.
12. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352(25): 2589-2597.
13. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552-3559.
14. Douillard JY, Tribodet H, Aubert D et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010; 5(2): 220-228.
15. Azzoli CG, Baker S Jr., Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27(36): 6251-6266.
16. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99(11): 847-857.
17. Gandara DR, Crowley J, Livingston RB et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11(5): 873-878.
18. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(21): 3543-3551.
19. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27(8): 1227-1234.
20. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
21. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-957.
22. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373(9674): 1525-1531.
23. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22(11): 2184-2191.
24. Gatzemeier U, von Pawel J, Vynnychenko I et al. FLEX: cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus CT alone in the 1st-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3(11): 4.
25. O'Byrne KJ, BI, Barrios C et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009; 27: 15s (suppl abstract 8007).
26. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28(6): 911-917.
27. Pujol JL, LT, Rosell R et al. A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 2009; 7: S508; 9009.
28. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25(12): 1545-1552.
29. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22(5): 777-784.
30. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785-794.
31. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899.
32. Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-smallcell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15(3): 419-426.
33. Hainsworth JD, Spigel DR, Farley C et al. Weekly docetaxel versus docetaxel/ gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110(9): 2027-2034.
34. Langer CJ, O'Byrne KJ, Socinski MA et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapynaive advanced non-small cell lung cancer. J Thorac Oncol 2008; 3(6): 623-630.
35. Lilenbaum R, Axelrod R, Thomas S et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26(6): 863-869.
36. Gridelli C, Maione P, Colantuoni G, Rossi A. Chemotherapy of non-small cell lung cancer in elderly patients. Curr Med Chem 2002; 9(16): 1487-1495.
37. The Elderly Lung Cancer Viborelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
38. Barlesi F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced nonsmall cell lung cancer: a systematic review. Lung Cancer 2006; 51(2): 159-172.
39. Weiss GJ, Rosell R, Fossella F et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007; 18(3): 453-460.
40. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095-2103.
41. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18(12): 2354-2362.
42. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589-1597.
43. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372(9652): 1809-1818.
44. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.
45. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527-1537.
46. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(26): 4268-4275.
47. Hirsch FR, Varella-Garcia M, Bunn PA Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21(20): 3798-3807.
48. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15(16): 5267-5273.
49. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23(11): 2513-2520.
50. Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12 (3 Pt 1): 839-844.
51. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25(5): 587-595.
52. Camidge DR, Kabbinavar F, Martins R. EGFR biomarker-selected randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (C/P) in chemo-naive advanced NSCLC. J Thorac Oncol 2008; 3: S268.
53. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561-566.
54. Bang Y, KE, Shaw AT, Kwak EL. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010; 28: 3.
55. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363(18): 1734-1739.